Article
A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer.
Oncotarget - 13 Sept 2016
Malorni Luca, Piazza Silvano, Ciani Yari, Guarducci Cristina, Bonechi Martina, Biagioni Chiara, Hart Christopher D, Verardo Roberto, Di Leo Angelo, Migliaccio Ilenia
Abstract excerpt
Palbociclib is a CDK4/6 inhibitor that received FDA approval for treatment of hormone receptor positive (HR+) HER2 negative (HER2neg) advanced breast cancer. To better personalize patients treatment it is critical to identify subgroups that would mostly benefit from it. We hypothesize that complex alterations of the Retinoblastoma (Rb) pathway might be implicated in resistance to CDK4/6 inhibitors and aim to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.